This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Prabhakaran, D. Articles by Anand, S. S Search for Related Content PubMed PubMed Citation Articles by Prabhakaran, D. Articles by Anand, S. S Social Bookmarking                         What's this?

The metabolic syndrome: an emerging risk state for cardiovascular disease

Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Canada

Sonia S Anand

Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Canada, Department of Medicine, McMaster University, Hamilton, Canada

The common clustering of glucose intolerance, insulin resistance, abdominal adiposity, elevated blood pressure, and low HDL cholesterol is referred to as metabolic syndrome. Individuals with this syndrome have an increased risk of developing cardiovascular disease (CVD). The World Health Organisation and the National Cholesterol Education Programme’s Adult Treatment Panel III (NCEP-ATP III) have outlined specific diagnostic criteria for the diagnosis of the metabolic syndrome to help in the Identification of this syndrome in clinical practice. While the WHO criteria were specifically developed for use in research, the NCEP criteria are useful in clinical diagnosis of the metabolic syndrome. The metabolic syndrome is amenable to lifestyle modifications such as increased physical activity, weight loss, and possibly intake of low-glycemic foods. Drug therapy may be used to treat individual components of the syndrome such as elevated blood pressure and dyslipidemia. To control elevated glucose levels (when there is failure of lifestyle modification), medications such as metformin, thiazolidinedione derivatives and alpha glucosidase inhibitors may be used.

Key Words: cardiovascular disease • factor analysis • lifestyle modification • metabolic syndrome

Vascular Medicine, Vol. 9, No. 1, 55-68 (2004)
DOI: 10.1191/1358863x04vm515ra


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Reiter, S. Wirth, A. Pourazim, S. Puchner, M. Baghestanian, E. Minar, and R. A. Bucek Skin tissue cholesterol is not related to vascular occlusive disease Vascular Medicine, May 1, 2007; 12(2): 129 - 134. [Abstract] [PDF]

				D. Prabhakaran, V. Chaturvedi, P. Shah, A. Manhapra, P. Jeemon, B. Shah, and K. Srinath Reddy Differences in the prevalence of metabolic syndrome in urban and rural India: a problem of urbanization Chronic Illness, March 1, 2007; 3(1): 8 - 19. [PDF]

				A. M. van den Hoek, A. C. Heijboer, P. J. Voshol, L. M. Havekes, J. A. Romijn, E. P. M. Corssmit, and H. Pijl Chronic PYY3-36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice Am J Physiol Endocrinol Metab, January 1, 2007; 292(1): E238 - E245. [Abstract] [Full Text] [PDF]

				R. D. Sheth Metabolic concerns associated with antiepileptic medications Neurology, November 23, 2004; 63(10_suppl_4): S24 - S29. [Abstract] [Full Text]